592 related articles for article (PubMed ID: 29385735)
21. Amyloid β-peptide and Alzheimer's disease.
Allsop D; Mayes J
Essays Biochem; 2014; 56():99-110. PubMed ID: 25131589
[TBL] [Abstract][Full Text] [Related]
22. Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development.
Varshavskaya KB; Mitkevich VA; Makarov AA; Barykin EP
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499362
[TBL] [Abstract][Full Text] [Related]
23. Amyloid-β Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity.
Guivernau B; Bonet J; Valls-Comamala V; Bosch-Morató M; Godoy JA; Inestrosa NC; Perálvarez-Marín A; Fernández-Busquets X; Andreu D; Oliva B; Muñoz FJ
J Neurosci; 2016 Nov; 36(46):11693-11703. PubMed ID: 27852777
[TBL] [Abstract][Full Text] [Related]
24. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
25. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
Takahashi T; Mihara H
Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
[TBL] [Abstract][Full Text] [Related]
26. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
[TBL] [Abstract][Full Text] [Related]
27. [Enalaprilat Inhibits Zinc-Dependent Oligomerization of Metal-Binding Domain of Amyloid-beta Isoforms and Protects Human Neuroblastoma Cells from Toxic Action of these Isoforms].
Kozin SA; Polshakov VI; Mezentsev YV; Ivanov AS; Zhokhov SS; Yurinskaya MM; Vinokurov MG; Makarov AA; Mitkevich VA
Mol Biol (Mosk); 2018; 52(4):683-691. PubMed ID: 30113034
[TBL] [Abstract][Full Text] [Related]
28. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.
Teng E; Taylor K; Bilousova T; Weiland D; Pham T; Zuo X; Yang F; Chen PP; Glabe CG; Takacs A; Hoffman DR; Frautschy SA; Cole GM
Neurobiol Dis; 2015 Oct; 82():552-560. PubMed ID: 26369878
[TBL] [Abstract][Full Text] [Related]
29. Beta-amyloid, neuronal death and Alzheimer's disease.
Carter J; Lippa CF
Curr Mol Med; 2001 Dec; 1(6):733-7. PubMed ID: 11899259
[TBL] [Abstract][Full Text] [Related]
30. A Synthetic Pro-Drug Peptide Reverses Amyloid-β-Induced Toxicity in the Rat Model of Alzheimer's Disease.
Kumar S; Srivastav S; Fatima M; Giri RS; Mandal B; Mondal AC
J Alzheimers Dis; 2019; 69(2):499-512. PubMed ID: 30958369
[TBL] [Abstract][Full Text] [Related]
31. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
32. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
33. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
[TBL] [Abstract][Full Text] [Related]
34. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
35.
Jean L; Brimijoin S; Vaux DJ
J Biol Chem; 2019 Apr; 294(16):6253-6272. PubMed ID: 30787102
[TBL] [Abstract][Full Text] [Related]
36. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease.
Rezvani Boroujeni E; Hosseini SM; Fani G; Cecchi C; Chiti F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019683
[TBL] [Abstract][Full Text] [Related]
37. Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis.
Penke B; Szűcs M; Bogár F
Molecules; 2020 Apr; 25(7):. PubMed ID: 32260279
[TBL] [Abstract][Full Text] [Related]
38. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?
Klein WL; Krafft GA; Finch CE
Trends Neurosci; 2001 Apr; 24(4):219-24. PubMed ID: 11250006
[TBL] [Abstract][Full Text] [Related]
39. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
[TBL] [Abstract][Full Text] [Related]
40. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.
Takahashi RH; Nagao T; Gouras GK
Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
